更年期综合征患者雌激素替代治疗对胰岛素样生长因子-1及骨密度的影响

Abstract
Figure/Table
References (18)
Related Citation (3)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the changes of serum insulin－like growth factor－1(IGF－1)and bone mineral density (BMD)before and after estrogen－replacement therapy in patients with climacteric syndrome.MethodsFrom June 2014 to June 2016,100 patients with menopausal syndrome admitted in our hospital were selected as objects and were randomly divided into research group and control group according to the order of visiting doctors,50 cases in each group.In the control group,routine treatment was used,while in the research group,on the basis of routine treatment,oraladministration of Estrdiolvlerte Tablet/Estradiol Progesterone Tablet for 6 continuous months.The Kupperman score,total effective rate,serum estradiol,insulin－like growth factor－1 (IGF－1)level,speed of ultrasound in tibia and radius were compared in research group and control group.ResultsAfter treatment,the improved Kupperman score of the research group was lower than the control group,and the difference was statistically significant(P＜0.05).The total apparent efficiency(94.0%)was higher than the control group(78.0%),and the difference was statistically significant(P＜0.05).After treatment,the serum E2and IGF－1 levels of the patients in the research group were higher than the control group,and the difference was statistically significant(P＜0.05).After treatment,the spread of tibial and radial ultrasound in the research group were higher than before treatment,and the differences were statistically significant(P＜0.05).ConclusionE-strogen－replacement therapy can increase the estrogen level,thereby alleviate the clinical symptoms of patients with menopausal syndrome,but also increase the level of serum IGF－1 and improve patient′s osteoporosis.

Key words： Menopausal syndrome Estrdiolvlerte Tablet/Estradiol Progesterone Tablet Bone mineral density Insulin－like growth factor－1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Juan-wen
	CHEN Wei-wei
	WANG Hui-qin
	ZHAO Hui-feng
	LI Hui

Cite this article:

MA Juan-wen,CHEN Wei-wei,WANG Hui-qin, et al. Influence of estrogen-replacement therapy on insulin-like growth factor-1 and bone mineral density in patients with menopausal syndrome[J]. 中国当代医药, 2017, 24(29): 71-74.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I29/71

[1]	Palacios S，Mejia A，Neyro J.Treatment of the genitourinary syndrome of menopause[J].Climacteric，2015，18（1），23－29.
[2]	Maghraoui A，Rezqi A，Mrahi S，et al.Osteoporosis，vertebral fracturesandmetabolicsyndromeinpostmenopausalwomen[J].BMC Endocr Disord，2014，14（1）：93.
[3]	Stefanska A，Bergmann K，Sypniewska G.Metabolic syndrome and menopause：pathophysiology，clinical and diagnostic significance[J].Adv Clin Chem，2015，72：1－75.
[5]	蒋建发，孙爱军.中老年女性骨质疏松症流行病学现状、分类及诊断[J].中国实用妇科与产科杂志，2014，30（5）：323－326.
[7]	Rahn D，Carberry C，Sanses T，et al.Vaginal estrogen for genitourinary syndrome of menopause：a systematic review[J].Obstet Gynecol：2014，124（6）：1147－1156.
[4]	Liu W，Yang L，Kong X，et al.Meta－analysis of osteoporosis：fracture risks，medication and treatment[J].Minerva Med，2015，106（4）：203－214.
[6]	Santen R，Kagan R，Altomare C，et al.Current and evolving approaches to individualizing estrogen receptor－based therapy for menopausal women[J].J Clin Endocrinol Metab，2014，99（3）：733－747.
[8]	Stuenkel C，Davis S，Gompel A，et al.Treatment of symptoms of the menopause：an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab，2015，100（11）：3975-4011.
[9]	Tao M，Shao H，Li C，et al.Correlation between the modified Kupperman index and the menopause rating scale in chinese women[J].Patient Prefer Adherence，2013，7：223-229.
[10]	Gandhi J，Chen A，Dagur G，et al.Genitourinary syndrome of menopause：an overview of clinical manifestations，pathophysiology，etiology，evaluation，and management[J].Am J Obstet Gynecol，2016，215（6）：704-711.
[11]	Indhavivadhana S，Rattanasrithong P.The relationship between bone mineral density and metabolic syndrome in peri-and post-menopausal thai women[J].Arch Gynecol Obstet，2015， 292（5）：1127-1133.
[12]	Fujita K，Roforth M，Demaray S，et al.Effects of estrogen on bone mrna levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women[J].J Clin Endocrinol Metab，2014，99（1）：81-88.
[13]	Klein-NulendJ，OersR，BakkerA，etal.Bonecellmechanosensitivity，estrogen deficiency，and osteoporosis[J].J Biomech，2015，48（5）：855-865.
[14]	Lambert T，Thybo C，Lykkeboe S，et al.Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women：a randomized controlled trial[J].Am J Clin Nutr，2017，106（3）：99.
[15]	Streicher C，Heyny A，Andrukhova O，et al.Estrogen regulates bone turnover by targeting rankl expression in bone lining cells[J].Sci Rep，2017，7(1)：6460.
[16]	Ashpole N，Herron J，Mitschelen M，et al.IGF-1 regulates vertebral bone aging through sex-specific and time-dependent mechanisms[J].J Bone Miner Res，2016，31（2）：443-454.
[17]	Farquharson C，Ahmed S.Inflammation and linear bone growth：the inhibitory role of SOCS2 on GH/IGF-1 signaling[J].Pediatr Nephrol，2013，28（4）：547-556.
[18]	Poudel S，Bhattarai G，Kook SH，et al.Recombinant human IGF-1 produced by transgenic plant cell suspension culture enhances new bone formation in calvarial defects[J].Growth Horm IGF Res，2017，30（36）：1-10.